

# Time-dependent ROC curve analysis to determine the predictive capacity of seven clinical scales for mortality in patients with COVID-19: Study of a hospital cohort with very high mortality

MARTHA A. MENDOZA-HERNANDEZ<sup>1,2</sup>, GUSTAVO A. HERNANDEZ-FUENTES<sup>1</sup>,  
CARMEN A. SANCHEZ-RAMIREZ<sup>1</sup>, FABIAN ROJAS-LARIOS<sup>1</sup>, JOSE GUZMAN-ESQUIVEL<sup>3</sup>,  
IRAM P. RODRIGUEZ-SANCHEZ<sup>4</sup>, MARGARITA L. MARTINEZ-FIERRO<sup>5</sup>, MARTHA I. CARDENAS-ROJAS<sup>3,6</sup>,  
LUIS DE-LEON-ZARAGOZA<sup>6</sup>, BENJAMIN TRUJILLO-HERNANDEZ<sup>1</sup>, MERCEDES FUENTES-MURGUIA<sup>1</sup>,  
HÉCTOR OCHOA-DÍAZ-LÓPEZ<sup>7</sup>, KARMINA SÁNCHEZ-MEZA<sup>1</sup> and IVAN DELGADO-ENCISO<sup>1,6</sup>

<sup>1</sup>Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico;

<sup>2</sup>COVID Unit, General Hospital Number 1, Mexican Institute of Social Security, Villa de Alvarez, Colima 28984, Mexico;

<sup>3</sup>Clinical Epidemiology Research Unit, Mexican Institute of Social Security, Villa de Alvarez, Colima 28984, Mexico;

<sup>4</sup>Molecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nuevo Leon,

San Nicolas de los Garza 66455, Mexico; <sup>5</sup>Molecular Medicine Laboratory, Academic Unit of Human Medicine and

Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico; <sup>6</sup>Department of Research,

Colima Cancerology State Institute, IMSS-Bienestar Colima, Colima 28085, Mexico; <sup>7</sup>Department of Health,

El Colegio de La Frontera Sur, San Cristóbal de Las Casas, 29290 Chiapas, Mexico

Received February 12, 2024; Accepted April 12, 2024

DOI: 10.3892/br.2024.1788

**Abstract.** Clinical data from hospital admissions are typically utilized to determine the prognostic capacity of Coronavirus disease 2019 (COVID-19) indices. However, as disease status and severity markers evolve over time, time-dependent receiver operating characteristic (ROC) curve analysis becomes more appropriate. The present analysis assessed predictive power for death at various time points throughout patient hospitalization. In a cohort study involving 515 hospitalized patients (General Hospital Number 1 of Mexican Social Security Institute, Colima, Mexico from February 2021 to December 2022) with COVID-19, seven severity indices [Pneumonia Severity Index (PSI) PaO<sub>2</sub>/FiO<sub>2</sub> arterial oxygen pressure/fraction of inspired oxygen (Kirby index), the Critical Illness Risk Score (COVID-GRAM), the National Early Warning Score 2 (NEWS-2), the quick Sequential Organ Failure Assessment score (qSOFA), the Fibrosis-4 index (FIB-4) and the Viral Pneumonia Mortality Score (MuLBSTA) were evaluated using time-dependent ROC curves. Clinical data were collected at admission and at 2, 4, 6 and 8 days into hospitalization. The study

calculated the area under the curve (AUC), sensitivity, specificity, and predictive values for each index at these time points. Mortality was 43.9%. Throughout all time points, NEWS-2 demonstrated the highest predictive power for mortality, as indicated by its AUC values. PSI and COVID-GRAM followed, with predictive power increasing as hospitalization duration progressed. Additionally, NEWS-2 exhibited the highest sensitivity (>96% in all periods) but showed low specificity, which increased from 22.9% at admission to 58.1% by day 8. PSI displayed good predictive capacity from admission to day 6 and excellent predictive power at day 8 and its sensitivity remained >80% throughout all periods, with moderate specificity (70.6-77.3%). COVID-GRAM demonstrated good predictive capacity across all periods, with high sensitivity (84.2-87.3%) but low-to-moderate specificity (61.5-67.6%). The qSOFA index initially had poor predictive power upon admission but improved after 4 days. FIB-4 had a statistically significant predictive capacity in all periods (P=0.001), but with limited clinical value (AUC, 0.639-0.698), and with low sensitivity and specificity. MuLBSTA and IKIRBY exhibited low predictive power at admission and no power after 6 days. In conclusion, in COVID-19 patients with high mortality rates, NEWS-2 and PSI consistently exhibited predictive power for death during hospital stay, with PSI demonstrating the best balance between sensitivity and specificity.

*Correspondence to:* Dr Ivan Delgado-Enciso, Department of Molecular Medicine, School of Medicine, University of Colima, 333 Av. Universidad, Colonia las Viboras, Colima 28040, Mexico  
E-mail: ivan\_delgado\_enciso@ucol.mx

**Key words:** COVID-19, severity of illness index, hospital mortality, ROC curve, sensitivity, specificity

## Introduction

Coronavirus disease 2019 (COVID-19) illness, stemming from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), posed a critical emergency for healthcare

systems during the first 3 years of the pandemic (1). However, the World Health Organization has advised maintaining readiness and vigilance across healthcare systems at all levels to address potential increases in outpatient cases and hospitalization, especially during peak periods of other communicable diseases with high care demand (2).

Despite most infections being self-limiting (3), the number of cases made COVID-19 one of the leading causes of mortality worldwide from 2020 to 2022. Nonetheless, this trend has diminished in recent years, partly due to vaccination strategies (4,5).

The prevalence of severe/critical COVID-19 cases and the need for hospitalization may vary based on regional factors (6). Globally, hospitalized patients with COVID-19 experienced mortality rates ranging from 1 to 52% (7), varying significantly based on the pandemic stage, ethnic and sociocultural characteristics, as well as vaccination or treatment strategies (8).

In Mexico, the overall hospital case mortality rate between March 2020 and August 2022 was 45.1% (95% CI, 44.9, 45.3), reaching a peak of 50.8% (9). This was one of the highest mortality rates among hospitalized patients with COVID-19 globally (10). Up to January 2024, Mexico has reported a total of 7,633,355 confirmed cumulative COVID-19 cases and >334,336 deaths (11,12).

The emergency caused by COVID-19 has led to the necessity and implementation of clinical instruments with high predictive value to support decision-making in patients with severe and critical illness (12). Various clinical risk scales and severity indices for respiratory disease and the progression of organ failure have been implemented to monitor patients hospitalized due to COVID-19. Although some of these scales were developed to monitor bacterial infection, they have been adapted for use in COVID-19, such as the Pneumonia Severity Index (PSI), the National Early Warning Score 2 (NEWS-2) and the Quick Sepsis-Related Organ Failure Assessment Score (qSOFA) (13-15). Other scales were specifically created for COVID-19, such as Viral Pneumonia Mortality Score (MuLBSTA: multilobular infiltration, hypo-lymphocytosis, bacterial coinfection, smoking history, hypertension, and age) and COVID-Guangzhou Institute of Respiratory Health Calculator at Admission (GRAM) (16,17). The Kirby Index ( $\text{PaO}_2/\text{FiO}_2$ , arterial oxygen pressure/fraction of inspired oxygen) is a tool used to measure lung capacity and functionality, particularly for diagnosing and prognosticating the severity of acute respiratory distress syndrome (18,19). The liver fibrosis index (FIB-4) is another scale that is worth studying, because previous studies showed that it has promising predictive power for mortality rate in patients with COVID-19, without underlying liver disease and in all age groups (20,21).

Nevertheless, the prognostic capacity of these scales in COVID-19 has typically been evaluated through receiver operating characteristic (ROC) curve analysis using only clinical data or markers at hospital admission or within the first 48 h of hospitalization (22-24). However, it is evident that both the disease status and the value of clinical markers used in the scales are changing over time, especially in hospitalized patients with COVID-19 (25). Therefore, in diseases with changing clinical states, it has been proposed that to assess the predictive power of certain markers or indices, it is more appropriate to use time-dependent ROC curve analysis (26).

ROC curves are generated at different time points to determine if a severity scale maintains its predictive capacity consistently or if it may weaken or strengthen as the target time moves away from the baseline (26).

The present study aimed to assess the predictive capacity for mortality of seven commonly used clinical indicators (PSI and Kirby index, COVID-GRAM, NEWS-2, qSOFA, FIB-4 and MuLBSTA) in patients with severe and critical COVID-19 upon admission and at 2, 4, 6 and 8 days of hospitalization using time-dependent ROC curve analysis. These clinical indicators were selected because they have been demonstrated utility in predicting mortality and severity in patients with respiratory disease, including COVID-19. These tools incorporate clinical parameters such as vital signs, laboratory results, and comorbidities to provide a comprehensive assessment of patient prognosis. Additionally, they have been previously validated in similar patient populations and have shown promising results in predicting outcomes in patients with COVID-19. Furthermore, the effectiveness of these predictive tools relies on the availability of relevant data types, including clinical observations, laboratory results, and patient demographics (15,16,18,20,27-29). The present study aimed to identify severity indices maintaining consistent predictive capacity in patients with fluctuating health status, such as those hospitalized with COVID-19, within a cohort exhibiting one of the highest mortality rates globally.

## Materials and methods

*Study design.* An ambispective (bidirectional) cohort study was conducted longitudinally with data collected from patients with severe and/or critical (30) COVID-19 who were hospitalized from February 2021 to December 2022 at the COVID-19 unit at General Hospital Number 1 of the Mexican Institute of Social Security (IMSS)-Colima (Colima, Mexico). The study was conducted in compliance with the Declaration of Helsinki and was approved by the local health research committee of General Hospital Number 1 of IMSS-Colima (approval no. R-2021-601-014). Following national legislation and institutional protocols, the local health research committee waived the requirement for written consent from patients involved in this observational study (article 23 of the Regulations of the General Health Law on Health Research in Mexico) (31,32) as it solely entailed analyzing data from a hospital database, posing no risk to patients. Patient confidentiality was maintained throughout the study, which was classified as low risk (31).

*Patients.* The inclusion criteria were non-pregnant patients aged >18 years diagnosed with COVID-19 based on positive results from Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription PCR (SARS-CoV-2 RT-PCR) or antigen tests. The study enrolled patients admitted to regular hospital floors, high-flow oxygen rooms, or intensive care units. Exclusion criteria included patients receiving only emergency room care without admission and those with incomplete clinical records. 515 patients were included in the analysis. The median age was  $63.3 \pm 16.1$  years, with a percentage of male patients was 61.9% and the percentage of female patients was 38.1%.

*Measures and follow-up.* Patient information, including medical history, COVID-19 vaccination status and clinical parameters from admission to discharge (due to either improvement or death), was retrieved from clinical records. Data collected included age, sex, medical history (comorbidities, Charlson comorbidity index score) (33), history of prior COVID-19 infection, smoking status (based on the Glossary of the National Health Interview Survey of the United States of America) (34), admission disease phase (severe/critical), clinical, laboratory and imaging data for each day of hospitalization, and reason for discharge (death or improvement). Arterial hypertension was identified by criteria aligned with the guidelines set forth by the Eighth Joint National Committee (JNC 8) for hypertension; these criteria encompassed a documented history in the clinical records (prior to hospitalization due to COVID-19 infection) of blood pressure readings equal to or exceeding 140/90 mmHg, a prior diagnosis of hypertension, or a positive record of antihypertensive therapy (35,36).

Data collected during hospitalization included variables necessary to calculate the scores of severity scales, laboratory parameters (such as D-dimer, ferritin, markers of renal or liver function, complete blood count), use of mechanical ventilation or hemodialysis and administration of medication (paracetamol, anticoagulants, antibiotics, vasopressors, steroids, and diuretics).

The seven severity and clinical risk index scores [PSI (12), Kirby index (9), COVID-GRAM (19), NEWS-2 (37), qSOFA (38), MuLBSTA (30) and FIB-4 (39,40)] were calculated upon admission and at 2, 4, 6 and 8 days of hospital stay (Table SI-SVII).

PSI (41) is a tool for stratifying the severity of patients with community-acquired pneumonia (42). PSI scale categorizes patients into five categories based on age, pre-existing comorbidity, physical examination, and clinical analysis results (37,43).

Kirby index ( $\text{PaO}_2/\text{FiO}_2$ ) has been widely used to classify acute respiratory distress syndrome due to its simplicity and diagnostic and prognostic capacity (18,44). The 2011 Berlin definition (38) was considered as it presents better predictive validity for mortality. Kirby index establishes the degree of hypoxemia as mild ( $200 < \text{PaO}_2/\text{FiO}_2 \leq 300$ ), moderate ( $100 < \text{PaO}_2/\text{FiO}_2 \leq 200$ ) and severe ( $\text{PaO}_2/\text{FiO}_2 \leq 100$  mmHg) (38,44).

COVID-GRAM (45) was developed to predict critical illness in patients with COVID-19 upon hospital admission. It comprises X-ray abnormality (yes/no), age, hemoptysis (yes/no), dyspnea (yes/no), unconsciousness (yes/no), number of comorbidities, history of cancer (yes/no), neutrophil-to-lymphocyte ratio, lactate dehydrogenase levels and direct bilirubin (46). This score considers the risk of developing critical COVID-19 as low (<1.7%), medium (1.7-<40.4%) (16) and high ( $\geq 40.4\%$ ) (16,46).

NEWS-2 (47) is based on a set of simple physiological variables to which a score is assigned. Currently, in its modified version, there are seven parameters: Respiratory rate, hypercapnic respiratory failure [partial pressure of carbon dioxide ( $\text{pCO}_2$ ) levels], oxygen saturation ( $\text{pO}_2$ ), systolic blood pressure, pulse rate, level of consciousness or new confusion (assessed according to Glasgow Coma Scale) (48) and body temperature. The combination of these values provides a score ranging from 0 to 20 (49,50).

qSOFA is used to clinically classify a septic patient and as a predictor of hospital mortality (27). It consists of clinical indicators including respiratory rate ( $\geq 22/\text{min}$ ), altered mental status, and altered systolic blood pressure ( $\leq 100$  mmHg), with each parameter generating a score from 0 to 3 (51). The components of qSOFA allow for an early and simple evaluation in hospital settings (25,27,51,52).

Viral Pneumonia Mortality Score (MuLBSTA) is composed of six parameters: Multilobular infiltration (yes/no), absolute lymphocyte count  $\leq 0.8 \times 10^9/\text{l}$  (yes/no), bacterial coinfection (detected by sputum or blood culture; yes/no), smoking history (no, inactive, active), history of hypertension (yes/no) and age  $\geq 60$  years (yes/no). The combination of these values provides a score ranging from 0 to 22 (29). Scores classified as follows: 0-11, low risk and 12-22, high risk of mortality (53). MuLBSTA score is considered to have potential clinical utility for stratifying the progression of SARS-CoV-2 disease (17).

FIB-4 index is a commonly used, used for non-invasive assessment of liver fibrosis in chronic liver disease due to its accessibility, cost-effectiveness, and validated reliability, offering a safer and more convenient alternative to invasive liver biopsy (20,21). It is calculated using four parameters: Age, levels of aspartate and alanine aminotransferase and platelet count. A score of  $\leq 1.3$  indicates low risk of fibrosis,  $>1.3$ -2.67 moderate risk and  $>2.67$  indicates high risk of fibrosis. (21,40). The FIB-4 score predicts mortality better than liver transaminases and may serve as a simple tool to identify patients with COVID-19 with a poorer prognosis in the emergency department (20,39).

*Statistical analysis.* Kolmogorov-Smirnov test was used to determine the normal distribution of data and Levene's test was used to confirm the equality of variances. Qualitative variables are expressed as absolute numbers or percentages, while quantitative variables are expressed as mean  $\pm$  standard deviation or 95% confidence intervals. Quantitative data with non-normal distribution are expressed as median and range or 25-75th percentile (Q1-Q3). Unpaired Student's t test was used to compare numerical data with normal distribution (body mass index and age) whereas Mann-Whitney U tests were used to compare data with non-normal distribution (length of hospital stay). Categorical values were compared using Fisher's exact test. Univariate linear mixed effects model tests were used to compare the evolution of clinical parameters (PSI, NEWS-2 and COVID-GRAM) between patients according to their reason for discharge (improvement or death; fixed effect) during the hospitalization period (repeated observations), employing two random variables (month of hospital admission and length of hospital stay). Additionally, mixed-effects multinomial logistic regression models were constructed for analysis of longitudinal nominal data [yes vs. no; patients in critical condition, with mechanical ventilation, elevated serum D-dimer, lactate dehydrogenase, ferritin, or blood urea nitrogen (BUN) or use of antibiotics or amines] comparing the basal values with the values of subsequent days. To determine predictive capacity for mortality of the clinical severity scales and indices, the areas under the ROC curve (AUCs) were calculated for the different scales with their 95% confidence intervals, cut-off point, P-values along with sensitivity, specificity, and predictive values upon admission and at 2, 4, 6, and




Figure 1. Flowchart of recruitment of hospitalized patients with COVID-19. COVID-19, Coronavirus Disease 2019.

8 days of hospitalization. Predictive capacity was classified based on AUC values as follows: 0.50-0.60 (failed), 0.61-0.70 (worthless), 0.71-0.80 (poor), 0.81-0.90 (good) and >0.90 (excellent), as previously described (54,55). Regarding the scales (PSI, Kirby index, COVID-GRAM, NEWS-2, qSOFA, MuLBSTA and FIB-4), the cut-off point was selected based on the point on the curve that provided the highest sensitivity and specificity (56). Sensitivity and specificity were classified as follows: High, >80; moderate, 65-80% and low, <65% (57). The statistical analysis was performed using SPSS software, version 20 (IBM Corp.).

## Results

**Patient characteristics and outcomes.** During the study period from February 1, 2021, to December 31, 2022 (Fig. 1), 1747 patients were admitted to the respiratory area of the internal medicine service at General Hospital Zone #1, Villa de Álvarez, Colima. Of these, 1,247 were excluded due to bacterial or influenza pneumonia (without COVID-19), pregnancy, age under 18 years and incomplete medical records, leaving 515 patients included in the analysis. The mean age was  $63.3 \pm 16.1$  years with differences between those who lived or died ( $60.9 \pm 16.7$  vs.  $66.7 \pm 14.2$  years, respectively). The percentage of male patients was 61.9%, with no differences regarding sex for mortality. Patients who died had a higher comorbidity index, use of amines, hemodialysis and invasive ventilatory support, as well as a higher score in all severity indices analyzed upon hospital admission (except Kirby index, where its value is inversely proportional to severity of the disease; Table I). The median length of hospital stay was a 7.0 days (range, 1-38), being shorter for patients discharged due to improvement (median of 4-6 days, range, 1-29) compared with those discharged due to death (median of 8.0 days, range, 1-38; Table I). The characteristics of patients upon admission, as well as the primary treatments used during hospitalization according to their final discharge status (alive or deceased), are summarized in Table I. A total of 31.9% of patients presented with critical illness at the time of admission. Mortality in the analyzed cohort was 43.9%.

**Variability of clinical markers during hospitalization.** Fig. 2A illustrates the progression of patient outcomes from admission (baseline) to day 8. A significant increase in patient mortality was observed. Specifically, on day 7, 44% of admitted patients died, while among those still hospitalized on day 7, the mortality rate increased to 53%. Similarly, on day 8, mortality rate further rose to 56%. In patients hospitalized with COVID-19, the disease state was not static; the proportion of patients with critical illness and requiring mechanical ventilation increased with time (Fig. 2B and C). Therefore, the value of clinical markers changed throughout the hospitalization period. The proportion of patients with elevated serum levels of D-dimer, lactate dehydrogenase, ferritin and BUN increased with hospital stay (Fig. 2D-G), as did the need for antibiotic treatment or support with amines (Fig. 2H and I). Furthermore, PSI, NEWS-2, and COVID-GRAM remained relatively constant over time, although their values differ depending on the reason for discharge from the hospital (improvement or death; Fig. 2J-L).

**Predictive capacity of mortality according to severity scales and indices over the course of hospitalization.** Table II shows predicted mortality at each time point. AUC was calculated to determine the optimal cut-off point for each variable in predicting death at different time points (Table II). For all time points, the index with the highest predictive power for mortality (according to its AUC values) was NEWS-2, followed by PSI and COVID-GRAM. These parameters increased predictive power as the hospitalization time progresses. NEWS-2 had good predictive power up to 2 and excellent power from 4 days h. NEWS-2 had the highest sensitivity to predict death (>96% in all periods evaluated), but its specificity was low (22.9% on admission to 58.1% on day 8 of hospitalization). PSI had good predictive capacity from admission to day 6 and excellent power at day 8. Its sensitivity was high (>80%) in all periods, with moderate specificity ranging from 70.6 to 77.3%. COVID-GRAM had good predictive capacity at all time points with high sensitivity (84.2-87.3%), albeit with low-to-moderate specificity (61.5-67.6%). The qSOFA index

Table I. Clinical characteristics of patients.

Characteristic	All (n=515)	Lived (n=289)	Died (n=226)	P-value
Mean age, years	63.3±16.1	60.9±16.7	66.7±14.2	<0.001 <sup>a</sup>
Median hospital stay, days (Q1-Q3)	7.0 (4-11)	6.0 (4-9)	8.0 (5-14)	<0.001 <sup>b</sup>
Male (%)	61.9	60.0	64.1	0.194 <sup>c</sup>
Mean BMI	30.3±6.9	30.3±6.8	30.7±6.7	0.726 <sup>a</sup>
Diabetes (%)	43.3	44.5	41.8	0.302 <sup>c</sup>
High blood pressure (%)	42.3	50.2	32.9	<0.001 <sup>c</sup>
COPD/asthma (%)	10.4	7.9	13.5	0.029 <sup>c</sup>
Smoker (%)	7.6	5.6	10.0	0.045 <sup>c</sup>
Cirrhosis (%)	3.5	3.2	3.8	0.439 <sup>c</sup>
Cancer (%)	0.4	0.4	0.4	0.704 <sup>c</sup>
CKD (%)	22.4	19.6	25.6	0.065 <sup>c</sup>
Autoimmune disease (%)	6.0	5.7	6.4	0.445 <sup>c</sup>
Heart disease (%)	3.5	2.5	4.7	0.135 <sup>c</sup>
Mean Charlson index	3.6±2.1	3.2±2.1	4.1±2.1	<0.001 <sup>a</sup>
Vaccinated (%)	43.9	51.2	35.0	<0.001 <sup>c</sup>
Critical COVID (%)	31.9	9.3	59.0	<0.001 <sup>c</sup>
Mean PSI	105.0±40.4	88.1±29.7	133.7±37.3	<0.001 <sup>a</sup>
Mean COVID-GRAM	128.0±35.2	116.8±2.3	9.6±3.2	<0.001 <sup>a</sup>
Mean NEWS	7.0±3.4	5.5±29.7	133.7±37.3	<0.001 <sup>a</sup>
Mean qSOFA	1.00±0.70	0.96±0.46	1.52±0.81	<0.001 <sup>a</sup>
Mean MuLBSTA	9.0±2.8	8.2±2.6	10.4±2.6	<0.001 <sup>a</sup>
Mean Kirby index	158.0±126.4	231.8±132.7	132.5±93.1	<0.001 <sup>a</sup>
Median FIB-4 (Q1-Q3)	1.63 (0.95-3.02)	1.35 (0.85-2.28)	2.16 (1-25-3.69)	<0.001 <sup>b</sup>
Treatment (%) <sup>c</sup>				
Paracetamol	11.3	12.5	9.8	0.213
Anticoagulants	90.5	88.6	92.7	0.074
Antibiotics	48.4	45.9	51.5	0.119
Amine support	8.6	2.5	15.8	<0.001
Steroids	92.9	95.7	92.0	0.003
Diuretics	14.2	13.7	14.8	0.408
Mechanical ventilation	32.0	3.6	66.2	<0.001
Hemodialysis	10.3	6.8	14.5	0.003

Analyzed by <sup>a</sup>unpaired student's t, <sup>b</sup>Mann-Whitney U and <sup>c</sup>Fisher's exact test. CKD, chronic kidney disease; PSI, pneumonia severity index; COVID-GRAM, Critical Illness Risk Score; NEWS, national early warning score; FIB-4, fibrosis-4; BMI, Body Mass Index; High blood pressure (%) was determined as a reading of 140/90 mmHg or higher, or by a prior diagnosis or treatment for hypertension, according to JNC 8 criteria (36,37); COPD, Chronic Obstructive Pulmonary Disease; COVID, Coronavirus Disease; qSOFA, quick Sequential Organ Failure Assessment score; MuLBSTA, the Viral Pneumonia Mortality Score. Q1-Q3: 25-75th percentile.

had an AUC with worthless predictive power (0.697) on the admission, improving its predictive capacity from 96 h (AUC, 0.842). MuLBSTA and Kirby index had poor predictive power on hospital admission (AUC, 0.726 and 0.748, respectively), with decreased after 6 days. Kirby index predictive power for patient survival is shown. MuLBSTA and qSOFA had high sensitivity at all time points (85-99%) with low specificity (14-33%). Kirby index showed low sensitivity (57.9% on day 0 and 57.1% on day 2) and high specificity in the first 2 days (82.5% on day 0 to 84.2% on day 2). However, after six days, both sensitivity and specificity decreased (45.7 and 59.4%, respectively). FIB-4 demonstrated statistically significant predictive capacity at all time points, albeit with limited

clinical value (AUC, 0.639-0.698) and showing low sensitivity and specificity. Fig. 3 plots the AUC of indices over time, showing that NEWS-2 and PSI had lowest predictive capacity, and this increased with length of hospital stay.

AUC was calculated to determine the optimal cut-off point for several common clinical biomarkers [neutrophil/lymphocyte ratio (NLR), serum lactate dehydrogenase (LDH), D-dimer, and ferritin) predicting death at various time points (Table III). All of these biomarkers exhibited variable predictive capacity depending on the evaluated time point. Although serum ferritin showed statistically significant predictive capacity at all time points, it was deemed worthless (Table III). LDH demonstrated poor predictive capacity in all analyses.




Figure 2. Clinical parameters and treatment of patients with COVID-19 over the first 8 days of hospitalization. (A) Proportion of patients who died or survived. Compared with baseline data, the proportion of patients who died increased significantly on days 7 ( $P=0.037$ ) and 8 ( $P=0.007$ ). (B) Proportion of patients in critical condition significantly increased on days 6 ( $P=0.024$ ), 7 ( $P=0.002$ ) and 8 ( $P<0.001$ ). (C) Proportion of patients requiring mechanical ventilation significantly increased on days 3 ( $P=0.034$ ) and 4-8 (all  $P<0.001$ ). (D) Proportion of patients with elevated serum D-dimer significantly increased on days 6-8 (all  $P<0.001$ ). (E) Proportion of patients with elevated serum lactate dehydrogenase significantly increased on days 5 ( $P=0.016$ ), 6 ( $P=0.036$ ), 7 ( $P=0.029$ ) and 8 ( $P=0.039$ ). (F) Proportion of patients with elevated serum ferritin significantly increased on days 2-8 (all  $P<0.001$ ). (G) Proportion of patients with elevated blood urea nitrogen significantly increased on days 6 ( $P=0.011$ ), 7 ( $P=0.001$ ) and 8 ( $P=0.006$ ). (H) Proportion of patients requiring antibiotics significantly increased on days 3 ( $P=0.014$ ), 4 ( $P=0.002$ ) and 5-8 (all  $P<0.001$ ). (I) Proportion of patients requiring amine therapy significantly increased on days 4 ( $P=0.009$ ), 5 ( $P=0.002$ ) and 6-8 (all  $P<0.001$ ). All comparisons were conducted using mixed-effects multinomial logistic regression analysis. \* $P<0.05$  vs. baseline. (J) National early warning score 2, (K) pneumonia severity index and (L) COVID-GRAM remained relatively constant over time, although their values differ depending on the reason for discharge from the hospital (improvement or death) \* $P<0.001$ . COVID-19, Coronavirus Disease 2019; COVID-GRAM, Critical Illness Risk Score.

NLR and D-dimer showed inadequate predictive ability on admission day (AUC 0.645 and 0.692, respectively) and the second day (AUC 0.649 and 0.652, respectively), but improved to poor on the fourth day (AUC, 0.754 and 0.728, respectively). Notably, NLR significantly enhanced its predictive capacity on days 6 and 8 of hospitalization (AUC 0.855 and 0.833, respectively), while D-dimer maintained poor predictive capacity (AUC 0.680 and 0.787, respectively).

## Discussion

In patients hospitalized with severe and critical COVID-19, there are variations among severity indices regarding their ability to predict death, which may also change as the hospital stay progresses. NEWS-2 and PSI were the best indices for predicting death in patients hospitalized with COVID-19 from admission to day 8, although PSI showed

Table II. Predictive capacity of PSI, Kirby index, COVID-GRAM, NEWS-2, qSOFA, MuLBSTA for mortality in patients with COVID-19.

A, Day 0								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
NEWS-2	0.857	0.823-0.891	<0.001	12.00	96.40	22.90	62.29	87.50
PSI	0.824	0.787-0.861	<0.001	114.00	80.40	70.60	76.73	74.88
COVID-GRAM	0.819	0.781-0.856	<0.001	142.00	87.30	61.50	72.81	80.34
MuLBSTA	0.726	0.682-0.770	<0.001	12.00	89.80	33.00	61.80	72.81
qSOFA	0.697	0.650-0.745	<0.001	3.00	98.90	14.00	57.99	91.42
Kirby	0.748	0.704-0.792	<0.001	198.00	57.90	82.50	79.89	61.93
FIB-4	0.639	0.029-0.583	<0.001	1.64	61.20	38.70	56.80	61.20
B, Day 2								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
NEWS-2	0.876	0.854-0.897	<0.001	12.00	96.90	30.30	62.73	89.10
PSI	0.832	0.806-0.857	<0.001	115.00	81.20	70.50	77.24	75.17
COVID-GRAM	0.816	0.789-0.843	<0.001	142.00	86.80	61.20	73.19	79.17
MuLBSTA	0.730	0.699-0.761	<0.001	12.00	90.00	33.50	62.69	72.90
qSOFA	0.744	0.713-0.775	<0.001	3.00	98.90	16.70	59.39	92.59
Kirby	0.768	0.731-0.805	<0.001	196.00	57.10	84.20	78.66	65.80
FIB-4	0.627	0.531-0.723	0.009	1.26	65.60	35.70	62.70	65.60
C, Day 4								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
NEWS-2	0.921	0.904-0.938	<0.001	12.00	97.60	33.70	64.87	91.87
PSI	0.866	0.841-0.890	<0.001	115.00	81.70	75.50	80.70	76.64
COVID-GRAM	0.824	0.797-0.852	<0.001	142.00	85.00	65.90	75.45	78.04
MuLBSTA	0.732	0.700-0.765	<0.001	12.00	88.90	33.80	62.83	70.68
qSOFA	0.842	0.817-0.867	<0.001	3.00	98.80	23.30	61.85	94.00
Kirby	0.659	0.573-0.740	<0.001	124.00	58.50	66.80	37.62	82.46
FIB-4	0.614	0.518-0.709	0.020	1.37	59.20	40.00	63.40	59.20
D, Day 6								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
NEWS-2	0.945	0.929-0.961	<0.001	11.00	98.30	49.10	66.73	96.53
PSI	0.887	0.862-0.912	<0.001	122.00	86.90	77.30	79.84	85.06
COVID-GRAM	0.822	0.791-0.854	<0.001	147.00	85.90	65.20	71.46	82.02
MuLBSTA	0.695	0.656-0.734	<0.001	12.00	86.30	32.60	57.16	69.62
qSOFA	0.877	0.853-0.902	<0.001	3.00	99.20	29.80	59.52	97.11
Kirby	0.535	0.425-0.645	0.308	119.00	45.70	59.40	18.82	84.16
FIB-4	0.699	0.599-0.799	<0.001	1.31	63.90	31.40	74.20	63.90
E, Day 8								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
NEWS-2	0.955	0.938-0.972	<0.001	11.00	99.10	58.10	65.68	58.10
PSI	0.901	0.874-0.928	<0.001	129.00	90.10	72.20	72.20	90.09
COVID-GRAM	0.829	0.792-0.866	<0.001	151.00	84.20	67.60	67.03	84.54

Table II. Continued.

E, Day 8								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
MuLBSTA	0.691	0.645-0.737	<0.001	12.00	85.30	33.30	50.93	73.60
qSOFA	0.892	0.865-0.919	<0.001	3.00	100.00	36.30	55.63	100.00
Kirby	0.569	0.427-0.711	0.253	123.00	51.90	56.30	16.09	87.85
FIB-4	0.698	0.579-0.816	≤0.001	1.34	59.7	29.70	77.60	59.70

A score equal to or higher than the cut-off point in NEWS-2, PSI, C-GRAM, MuLBSTA, and qSOFA is the predictor of patient death. In the Kirby Index, a score equal to or lower than the cut-off point is the predictor of patient death, showing the AUC value representing the predictive capacity for patient survival. AUC, area under the curve; SEN, sensitivity; SPEC, specificity; PPV, positive predictive value; NPV, negative predictive value; NEWS-2, National Early Warning Score 2; PSI, Pneumonia Severity Index; COVID-GRAM, Critical Illness Risk Score; MuLBSTA, Viral Pneumonia Mortality Score; qSOFA, Quick Sequential Organ Failure Assessment Score; FIB-4, Fibrosis-4.




Figure 3. Changes in predictive power (AUC, with 95% confidence intervals) during hospitalization for (A) National Early Warning Score, (B) Pneumonia Severity Index, (C) COVID-GRAM, (D) MuLBSTA, (E) Quick Sequential Organ Failure Assessment Score, (F) Kirby and (G) fibrosis-4 index. AUC, area under the curve; COVID-GRAM, Critical Illness Risk Score; MuLBSTA, the Viral Pneumonia Mortality Score.

the best balance between specificity and sensitivity. These results are consistent with those previously reported by Artero *et al* (58) in hospitals in Spain, where it was shown that PSI and CURB-65 were better than qSOFA and MuLBSTA at predicting mortality in patients with COVID-19 and

pneumonia, and that PSI had the highest sensitivity (84.1%) and specificity (72.2%). The predictive capability of PSI for hospital mortality was similar to that in other studies (AUC, 0.77-0.85) (22,24,59). The main drawback that has previously postulated on the PSI is the high score assigned to comorbidity



Table III. Predictive capacity of NLR, D-dimer, ferritin, and LDH for mortality in patients with COVID-19.

A, Day 0								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
NLR	0.645	0.596-0.695	<0.001	9.90	61.10	37.20	57.60	61.10
Dimer-D	0.692	0.611-0.772	<0.001	607.00	66.70	39.00	55.20	66.70
LDH	0.710	0.662-0.758	<0.001	355.00	59.10	29.00	63.80	59.10
Ferritin	0.586	0.511-0.660	0.024	634.00	54.10	44.20	48.20	54.10
B, Day 2								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
NLR	0.649	0.586-0.712	<0.001	10.50	61.80	39.40	56.30	61.80
Dimer-D	0.652	0.560-0.744	0.001	699.00	60.00	40.70	50.00	60.00
LDH	0.774	0.695-0.854	<0.001	351.00	68.90	29.20	66.70	68.90
Ferritin	0.607	0.518-0.696	0.018	783.00	53.60	45.20	46.80	53.60
C, Day 4								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
NLR	0.754	0.699-0.809	<0.001	11.50	71.10	29.30	69.70	71.10
Dimer-D	0.728	0.644-0.812	<0.001	935.00	66.70	35.20	63.80	66.70
LDH	0.794	0.721-0.867	<0.001	345.00	68.00	24.30	75.00	68.00
Ferritin	0.653	0.574-0.732	<0.001	665.00	60.20	39.30	61.50	60.20
D, Day 6								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
NLR	0.855	0.806-0.904	<0.001	12.75	69.70	21.60	79.00	69.70
Dimer-D	0.680	0.575-0.785	0.001	1411.00	60.40	38.30	64.00	60.40
LDH	0.792	0.703-0.881	<0.001	365.00	64.90	25.00	80.00	64.90
Ferritin	0.623	0.527-0.719	0.012	876.10	60.30	37.30	66.70	60.30
E, Day 8								
Index	AUC	95% CI	P-value	Cut-off value	SEN, %	SPEC, %	PPV, %	NPV, %
NLR	0.833	0.768-0.898	<0.001	14.14	68.80	19.70	82.10	68.80
Dimer-D	0.787	0.691-0.883	<0.001	1610.00	0.706	23.50	81.80	70.60
LDH	0.701	0.594-0.809	<0.001	365.50	60.00	34.20	73.50	60.00
Ferritin	0.640	0.539-0.742	0.007	985.90	62.90	35.80	67.20	62.90

A score equal to or higher than the cut-off point in NLR, D-dimer, ferritin, and LDH predicts patient death. AUC (area under the curve), SEN (sensitivity), SPEC (specificity), PPV (positive predictive value), and NPV (negative predictive value) are utilized. NLR represents neutrophil/lymphocyte ratio, LDH denotes Serum Lactate Dehydrogenase.

and age variables, which could bias the risk assessment, especially if other clinically relevant factors do not receive the same weight. This could result in an overestimation of risk for certain patients, potentially leading to inappropriate clinical decisions such as unnecessary hospitalization or

overly aggressive treatments (37,43), although this does not affect its predictive capacity in COVID-19.

The present study identified potential factors that could enhance the sensitivity and specificity of predictive models for mortality in patients with severe and critical COVID-19.

Longitudinal data on specific clinical markers such as NLT, or serum levels of D-dimer, lactate dehydrogenase and ferritin throughout the hospitalization period could assist clinicians in evaluating patient prognosis. However, utility of these markers varied, and they did not surpass the predictive capacity of PSI, NEWS-2, or COVID-GRAM indices. LDH exhibited poor predictive capacity, albeit consistent over time. Conversely, the markers D-dimer and NLR lacked predictive utility upon admission and on the second day, though their predictive capacity improved from day 4 onwards. NLR, which displayed good predictive capacity on days 6 and 8 (AUC 0.855 AND 0.833, respectively). These findings align with previous studies (10,60,61). Additionally, integrating demographic variables such as age, comorbidities, and vaccination status may predict prognosis for each patient (10). Use of steroids in the present cohort was significantly higher in patients who survived, which may have contributed to improved prognosis, consistent with evidence supporting the use of steroids in patients with COVID-19, especially those requiring mechanical ventilation (62). These insights underscore the importance of considering temporal trends in clinical markers, such as serum levels of D-dimer, which demonstrated increasing predictive power for mortality as hospitalization progressed.

While NEWS-2 has shown variability in its predictive capacity for mortality across different studies and populations, with an AUC of 0.68 (with low sensitivity and specificity) in the UK population, a study in the Spanish population obtained an AUC of 0.81, with moderate sensitivity and low specificity (12,47,49). Other indices, such as qSOFA, also show notable variability in their predictive capacity in different populations, ranging from an AUC of 0.67 to 0.95 (22,24,58). Therefore, there is a controversy assuming its relevance for predicting hospital mortality for various diseases (27,51,52). This is consistent with the results of the present report, where it showed variability in its predictive capacity, which ranged from worthless to good, at the different evaluation time points (AUC 0.69 to 0.89). Regarding the MuLBSTA scale, it has been considered to have potential clinical utility for stratifying the progression of SARS-CoV-2 disease. However, this has been established mainly in Asian and Indian populations and in mild-to-moderate COVID-19 disease (53,63), and in a Spanish cohort of hospitalized patients (64). Therefore, it was relevant to extrapolate the use of this scale in a Latin American population and to evaluate its use not only upon hospital admission and discharge. In hospitalized Spanish patients, the MuLBSTA scale had a poor predictive capacity (AUC 0.73) for mortality/mechanical ventilation, with the PSI and CURB-65 indices having better predictive capacity (64). This is consistent with the results of the present study, where the MuLBSTA scale demonstrates that it is capable of predicting the death of patients hospitalized with COVID-19, but with variability depending on the evaluation time during their hospital stay (AUC varies from 0.69 to 0.82). COVID-GRAM had good predictive capacity at all time points with high sensitivity (84.2-87.3%), albeit with low-to-moderate specificity (61.5-67.6%). The above is consistent with previous studies that report it as an index, which with a cut-off point ( $\geq 89$ ) similar to those found in the present work ( $> 86$ ), had a very high sensitivity (97.7%), but low specificity (32.7%) for developing critical illness (16,46).

The variability in the predictive capacity reported for severity indices in COVID-19 may be due to differences in characteristics of the analyzed populations, especially regarding risk factors (comorbidity, age, vaccination status, and therapeutic strategies), which are also reflected in the variations in the mortality rate in different cohorts analyzed (10,23,65). The present study was conducted in a cohort of hospitalized patients with COVID-19 with adverse prognosis and high mortality (45.5%, one of the highest in the world) (10) compared with other studies that had lower mortality rates, ranging from 2.3 to 30.5% (22-24,58). Another strength of the present study is that the predictive power was determined at different time points. Previous reports have generally evaluated the predictive power of indices only at hospital admission (22-24).

The present results reveal that there are indices whose predictive capacity remains relatively constant (COVID-GRAM, MuLBSTA and FIB-4), increase (NEWS-2, PSI, qSOFA) or decrease (Kirby index) as the hospital stay progresses. Each severity index is derived from clinical parameters, which may undergo varying degrees of change throughout hospitalization. Consequently, the predictive efficacy of each index may fluctuate based on the significance and temporal variability of the clinical parameters it encompasses. In particular, the variability in the predictive capacity of severity indices, including the decline in the predictive power of the Kirby index over time, could be influenced by the evolving clinical trajectory of the disease, heterogeneous manifestations of COVID-19 and factors such as patient demographics and treatment strategies (18). Further research is warranted to understand the underlying mechanisms driving these changes and to optimize integration of the Kirby index into clinical practice for prognostication in patients with COVID-19.

FIB-4 index was confirmed as a tool capable of predicting mortality in patients with COVID-19, which agrees with previous studies (20,21). Its predictive capacity remained consistent across the evaluated periods, although it was lower (AUC 0.639-0.698) compared with that previously reported in a Taiwanese population (AUC, 0.863) (20). These disparities may be because these populations exhibited significantly different mortality outcomes. For example, in the Taiwanese cohort ( $n=221$ ), the median FIB-4 on admission was 1.91, with 4.5% of patients succumbing to the illness, while in the present study ( $n=515$ ), these values were 4.68 and 43.9%, respectively (66).

The variations in the predictive capacity of severity indices among patients hospitalized with severe and critical COVID-19 underscore the complex nature of prognostication in this population. While NEWS-2 and PSI were the most reliable predictors of mortality, it is crucial to understand the factors contributing to the varying performance of indices over time. Notably, the present analysis revealed a decline in the predictive power of Kirby index over time, which may reflect the dynamic changes in lung function and oxygenation status during hospitalization.

In standard ROC curve analysis, a marker is measured at one time, assuming that the marker value (or index) remains fixed throughout the study period. However, in practice, both the disease state and level of prognostic biomarkers change over time (26). During the course of a disease, clinical status varies, making time-dependent ROC curve analysis appropriate. A

ROC curve can be generated at various time points and the predictive capacity of the marker can be compared (26). Therefore, the time-dependent ROC curve is an effective tool for measuring performance or robustness of a marker, given the changing clinical status. The predictive capacity of a marker may weaken or strengthen as the target time moves away from baseline. Using a time-dependent ROC curve for an index or marker that varies over time is most appropriate for guiding key medical decisions (26). This is relevant in conditions that can be highly fluctuating, such as COVID-19. In countries and hospitals with limited resources, it is key to obtain reliable clinical severity scales and indices that allow for effective and early medical care for patients at high risk of mortality. Identifying the best prognostic index, particularly one whose predictive power remains constant during hospital stay, is key. Therefore, the results of the present study can be useful for clinicians. There are other severity scores for community-acquired pneumonia such as The confusion, uremia, respiratory rate, BP, age  $\geq 65$  years) and A-DROP (age, dehydration, respiratory failure, orientation disturbance, and low blood pressure) scores, whose predictive utility is specifically established in patients aged  $>65$  and 70 years, respectively, as well as in bacterial pneumonia, with limited prognostic capacity for assessing severity in viral infection (67-69).

One important aspect is the possibility of simultaneously applying two or more scales during clinical course to assess their condition and guide treatment. While certain scales may not be effective at certain stages, they may provide valuable clinical insights for future considerations. This approach allows for a more comprehensive evaluation of the patient progression and enables clinicians to adapt treatment strategies, leveraging the strengths of different scales to optimize patient care over time. ROC curve provides a valuable tool for evaluating and enhancing performance of assessment scales. Strategies to improve scales may include incorporating new biomarkers, refining inclusion criteria, external validation, optimizing cutoff points and considering confounding factors. These strategies can enhance accuracy and reliability of scales, resulting in more effective and personalized clinical decision-making. However, one aspect that must be considered when the various predictive scales are used for clinical purposes is that currently there is no standard definition of high, moderate, or low specificity and/or sensitivity. Although this stratification has been used in various contexts (70,71), its interpretation depends on the clinical context and the specific disease or condition (57).

In conclusion, in hospitalized patients with COVID-19 and a high mortality rate, NEWS-2 scale has the best predictive power; it has high sensitivity but low specificity, indicating that it is unlikely to give a false negative result. Therefore, it would identify patients who are likely to die, but it would also inform patients who will not die of this possibility. NEWS-2 (a test with high sensitivity) can be useful for ruling out (with good certainty) the possibility of death if a person has a negative result. On the other hand, PSI also has good to excellent predictive capacity, but additionally has a more balanced sensitivity and specificity (high and moderate, respectively), making it a useful and practical indicator for clinical use. Additionally, in hospitalized patients with COVID-19, where the disease and severity indices can be variable, using time-dependent

ROC curves is an effective tool for measuring predictive performance of various indices. NEWS-2 and PSI indices were the most robust instruments for predicting patient death throughout hospital stay.

### Acknowledgements

The authors would like to thank Professor Julio V. Barrios Nuñez from University of Colima (Colima, Mexico) for assistance with English language editing.

### Funding

The present study was supported by the National Council of Humanities, Sciences, and Technologies (grant no. 319282; Call for Frontier Science, Modality: Paradigms and Controversies of Science).

### Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

### Authors' contributions

MAMH and IDE conceived and designed the study. MAMH, FRL, JGE, MICR and LDLZ reviewed the literature and collected patient information. IDE, GAHF, MLMF, BTH and HODL performed the statistical analysis. CASR, IPRS, MFM and KSM participated in the analysis/interpretation of the results, in addition to writing the manuscript. All authors revised the manuscript. All authors have read and approved the final manuscript. All authors confirm the authenticity of all the raw data.

### Ethics approval and consent to participate

The present study was conducted in accordance with the Declaration of Helsinki and approved by the local health research committee of General Hospital Number 1 of IMSS-Colima, Mexico (approval no. R-2021-601-014, June 30, 2021). Following national legislation and institutional protocols, the requirement for written consent was waived.

### Patient consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Authors' information

Martha A. Mendoza-Hernandez, ORCID no. 0000-0002-7646-0842

Gustavo A. Hernandez-Fuentes, ORCID no. 0000-0003-4685-3095

Carmen A. Sanchez-Ramirez, ORCID no. 0000-0002-3525-7821

Fabian Rojas-Larios, ORCID no. 0000-0003-1744-9173  
 Jose Guzman-Esquivel, ORCID no. 0000-0002-6727-0051  
 Iram P. Rodriguez-Sanchez, ORCID no. 0000-0002-5988-4168  
 Margarita L. Martinez-Fierro, ORCID no. 0000-0003-1478-9068  
 Martha I Cardenas-Rojas, ORCID no. 0000-0001-7117-5922  
 Luis De-Leon-Zaragoza, ORCID no. 0000-0003-3753-7541  
 Benjamin Trujillo-Hernandez, ORCID no. 0000-0001-8306-0137  
 Mercedes Fuentes-Murguia, ORCID no. 0000-0001-9632-7953  
 Héctor Ochoa-Díaz-López, ORCID no. 0000-0002-8421-4983  
 Karmina Sánchez-Meza, ORCID no. 0000-0002-8702-0252  
 Ivan Delgado-Enciso, ORCID no. 0000-0001-9848-862X

## References

- Barbero MG: ¿Como ha afectado la COVID- 19 al sistema sanitario y la formación de los médicos y que hemos aprendido? *Educación Médica* 22: S1-S2, 2021.
- Pan American Health Organization: Epidemiological update: SARS-CoV-2 and other respiratory viruses in the Americas Region-8 January 2024., 2024.
- Delgado-Enciso I, Paz-Garcia J, Barajas-Saucedo CE, Mokay-Ramírez KA, Meza-Robles C, Lopez-Flores R, Delgado-Machuca M, Murillo-Zamora E, Toscano-Velazquez JA, Delgado-Enciso J, *et al*: Safety and efficacy of a COVID-19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open-label, controlled trial. *Exp Ther Med* 22: 915, 2021.
- Mascellino MT, Di Timoteo F, De Angelis M and Oliva A: Overview of the main anti-SARS-CoV-2 vaccines: Mechanism of action, efficacy and safety. *Infect Drug Resist* 14: 3459-3476, 2021.
- Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, Kambhampati AK, Milucky J, Zell E, Moline HL, *et al*: COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US States, January 2021 to April 2022. *JAMA Intern Med* 182: 1071-1081, 2022.
- Chang D, Chang X, He Y and Tan KJK: The determinants of COVID-19 morbidity and mortality across countries. *Sci Rep* 12: 5888, 2022.
- Abate SM, Checkol YA and Mantefardo B: Global prevalence and determinants of mortality among patients with COVID-19: A systematic review and meta-analysis. *Ann Med Surg (Lond)* 64: 102204, 2021.
- Gray WK, Navaratnam AV, Day J, Wendon J and Briggs TWR: COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: An observational study. *Thorax* 77: 1113-1120, 2022.
- de Jesus Ascencio-Montiel I, Ovalle-Luna OD, Rascón-Pacheco RA, Borja-Aburto VH and Chowell G: Comparative epidemiology of five waves of COVID-19 in Mexico, March 2020-August 2022. *BMC Infect Dis* 22: 813, 2022.
- Mendoza-Hernandez MA, Guzman-Esquivel J, Ramos-Rojas MA, Santillan-Luna VV, Sanchez-Ramirez CA, Hernandez-Fuentes GA, Diaz-Martinez J, Melnikov V, Rojas-Larios F, Martinez-Fierro ML, *et al*: Differences in the evolution of clinical, biochemical, and hematological indicators in hospitalized patients with COVID-19 according to their vaccination scheme: A cohort study in one of the world's highest hospital mortality populations. *Vaccines (Basel)* 12: 72, 2024.
- COVID-19 Tablero México-CONACYT-CentroGeo-GeoInt-D ataLab.
- Myrstad M, Ihle-Hansen H, Tveita AA, Andersen EL, Nygård S, Tveit A and Berge T: National early warning score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19-a prospective cohort study. *Scand J Trauma Resusc Emerg Med* 28: 66, 2020.
- De Socio GV, Gidari A, Sicari F, Palumbo M and Francisci D: National early warning score 2 (NEWS2) better predicts critical Coronavirus Disease 2019 (COVID-19) illness than COVID-GRAM, a multi-centre study. *Infection* 49: 1033-1038, 2021.
- Heldt S, Neuböck M, Kainzbauer N, Shao G, Tschöellitsch T, Duenser M, Kaiser B, Winkler M, Para C, Meier J, *et al*: qSOFA score poorly predicts critical progression in COVID-19 patients. *Wien Med Wochenschr* 172: 211-219, 2022.
- Alanís-Naranjo JM, Anguiano-Álvarez VM, Hammeken-Larrondo EF and Olguín-Contreras G: Desempeño de PSI/PORT y SOFA para predicción de ventilación mecánica invasiva en neumonía por SARS-CoV-2. *Med Crít* 36: 155-160, 2022.
- Moreno-Pérez Ó, Andrés M, León-Ramírez JM, Sánchez-Payá J, Boix V, Gil J and Merino E: The COVID-GRAM tool for patients hospitalized with COVID-19 in Europe. *JAMA Intern Med* 181: 1000, 2021.
- George R, Mehta AA, Paul T, Sathyapalan DT, Haridas N, Kunoor A and Ravindran GC: Validation of MuLBSTA score to derive modified MuLB score as mortality risk prediction in COVID-19 infection. *PLoS Glob Public Health* 2: e0000511, 2022.
- Sandoval-Gutiérrez JL: A 40 años de la descripción del índice de Kirby (PaO2/FiO2). *Med Intensiva* 39: 521, 2015 (In Spanish).
- García-Pereña L, Sesma VR, Divieso ML, Carrascosa AL, Fuentes SV and Parra-Ruiz J: Beneficio del empleo precoz de la oxigenoterapia nasal de alto flujo (ONAF) en pacientes con neumonía por SARS-CoV-2. *Med Clin (Barc)* 158: 540-542, 2022 (In English, Spanish).
- Liu CY, Chou SF, Chiang PY, Sun JT, Tsai KC, Jaw FS, Chang CT, Fan CM, Wu YH, Lee PY, *et al*: The FIB-4 scores in the emergency department to predict the outcomes of COVID-19 patients in Taiwan. *Heliyon* 10: e25649, 2024.
- Schreiner AD, Moran WP, Zhang J, Livingston S, Marsden J, Mauldin PD, Koch D and Gebregziabher M: The association of fibrosis-4 index scores with severe liver outcomes in primary care. *J Gen Intern Med* 37: 3266-3274, 2022.
- Fan G, Tu C, Zhou F, Liu Z, Wang Y, Song B, Gu X, Wang Y, Wei Y, Li H, *et al*: Comparison of severity scores for COVID-19 patients with pneumonia: A retrospective study. *Eur Respir J* 56: 2002113, 2020.
- Sheerin T, Dwivedi P, Hussain A and Sivayoham N: Performance of the CURB65, NEWS2, qSOFA, SÓFA, REDS, ISARIC 4C, PRIEST and the novel COVID-19 severity scores, used to risk-stratify emergency department patients with COVID-19, on mortality-an observational cohort study. *COVID* 3: 555-566, 2023.
- Ahnert P, Creutz P, Horn K, Schwarzenberger F, Kiehnopf M, Hossain H, Bauer M, Brunkhorst FM, Reinhart K, Völker U, *et al*: Sequential organ failure assessment score is an excellent operationalization of disease severity of adult patients with hospitalized community acquired pneumonia-results from the prospective observational PROGRESS study. *Crit Care* 23: 110, 2019.
- Becerra-Muñoz VM, Núñez-Gil IJ, Eid CM, Aguado MG, Romero R, Huang J, Mulet A, Ugo F, Rametta F, Liebetau C, *et al*: Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19. *Age Ageing* 50: 326-334, 2021.
- Kamarudin AN, Cox T and Kolamunnage-Dona R: Time-dependent ROC curve analysis in medical research: Current methods and applications. *BMC Med Res Methodol* 17: 53, 2017.
- Goulden R, Hoyle MC, Monis J, Railton D, Riley V, Martin P, Martina R and Nsutebu E: qSOFA, SIRS and NEWS for predicting inhospital mortality and ICU admission in emergency admissions treated as sepsis. *Emerg Med J* 35: 345-349, 2018.
- Shahsavarinia K, Moharramzadeh P, Arvanagi RJ and Mahmoodpoor A: qSOFA score for prediction of sepsis outcome in emergency department. *Pak J Med Sci* 36: 668-672, 2020.
- Xinxin Z: MuLBSTA score for viral pneumonia mortality. *MDCalc*, 2020.
- World Health Organization (WHO): Clinical Management of COVID-19: Evolving Guidelines. WHO, Geneva, 2021.
- United Mexican States - Ministry of Health: Regulations of the General Health Law concerning Health Research. *Official Gazette of the Federation*: 1-31, 1987.
- Miranda-Navales MG and Villasis-Keever MÁ: El protocolo de investigación VIII. La ética de la investigación en seres humanos. *Rev Alerg Mex* 66: 115-122, 2019 (In Spanish).
- Charlson ME, Carrozzino D, Guidi J and Patierno C: Charlson Comorbidity index: A critical review of clinimetric properties. *Psychother Psychosom* 91: 8-35, 2022.
- National Center for Health Statistics: National Center for Health Statistics (NCHS) C for DC and P (CDC): Glossary. *National Health Interview Survey*, 2017.

35. Delgado-Enciso I, Gonzalez-Hernandez NA, Baltazar-Rodriguez LM, Millan-Guerrero RO, Newton-Sanchez O, Bayardo-Noriega A, Aleman-Mireles A, Enriquez-Maldonado IG, Anaya-Carrillo MJ, Rojas-Martinez A and Ortiz-Lopez R: Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population. *J Genet* 88: 249-252, 2009.
36. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Oggedegbe O, *et al*: 2014 evidence-based guideline for the management of high blood pressure in adults. *JAMA* 311: 507-520, 2014.
37. Jonathan B, Cilloniz C and Torres A: Community-acquired pneumonia (non COVID-19). *BMJ Best Practice* , 2023.
38. ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L and Slutsky AS: Acute respiratory distress syndrome: The Berlin definition. *JAMA* 307: 2526-2533, 2012.
39. Bucci T, Galardo G, Gandini O, Vicario T, Paganelli C, Cerretti S, Bucci C, Pugliese F and Pastori D; Research On Medical patients Admitted to the Emergency Department (ROMA-ED) study group: Fibrosis-4 (FIB-4) index and mortality in COVID-19 patients admitted to the emergency department. *Intern Emerg Med* 17: 1777-1784, 2022.
40. Kuma A, Mafune K, Uchino B, Ochiai Y, Miyamoto T and Kato A: Potential link between high FIB-4 score and chronic kidney disease in metabolically healthy men. *Sci Rep* 12: 16638, 2022.
41. DeLaney M and Khoury C: Community-acquired pneumonia in the emergency department. *Emerg Med Pract* 23: 1-24, 2021.
42. Wang D, Willis DR and Yih Y: The pneumonia severity index: Assessment and comparison to popular machine learning classifiers. *Int J Med Inform* 163: 104778, 2022.
43. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ and Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 336: 243-250, 1997.
44. Morales-Aguirre AM, Márquez-González H, Salazar-Rosales H, Álvarez-Valencia JL, Muñoz-Ramírez CM and Zárate-Castañón P: Cociente PaO<sub>2</sub>/FiO<sub>2</sub> o índice de Kirby: Determinación y uso en población pediátrica. *Residente* 10: 88-92, 2015.
45. QxMD Software Inc: COVID-GRAM critical illness risk score-MDCalc. *Medscape*, 2020.
46. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Guan W, Sang L, Lu J, *et al*: Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. *JAMA Intern Med* 180: 1081-1089, 2020.
47. Gary BS: National early warning score (NEWS) 2. *MDCalc*, 2020.
48. Teasdale G, Murray G, Parker L and Jennett B: Adding up the glasgow coma score. In: *Proceedings of the 6th European Congress of Neurosurgery*. Springer Vienna, Vienna, pp13-16, 1979.
49. Smith GB, Redfern OC, Pimentel MA, Gerry S, Collins GS, Malycha J, Prytherch D, Schmidt PE and Watkinson PJ: The national early warning score 2 (NEWS2). *Clin Med (Lond)* 19: 260, 2019.
50. Royal College of Physicians: Royal College of physicians. National early warning score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. Updated report of a working party. London: RCP. London, 2017.
51. Ferreira M, Blin T, Collercandy N, Szychowiak P, Dequin PF, Jouan Y and Guillon A: Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA. *Ann Intensive Care* 10: 43, 2020.
52. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M, *et al*: Assessment of clinical criteria for sepsis: For the third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 315: 762-774, 2016.
53. Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M and Qu J: Clinical features predicting mortality risk in patients with viral pneumonia: The MuLBSTA score. *Front Microbiol* 10: 2752, 2019.
54. Polo TCF and Miot HA: Aplicações da curva ROC em estudos clínicos e experimentais. *J Vasc Bras* 19: e20200186, 2020.
55. Safari S, Baratloo A, Elfil M and Negida A: Evidence based emergency medicine; part 5 receiver operating curve and area under the curve. *Emerg (Tehran)* 4: 111-113, 2016.
56. Unal I: Defining an optimal cut-point value in ROC analysis: An alternative approach. *Comput Math Methods Med* 2017: 1-14, 2017.
57. Evans HJ, Gibson NA, Bennett J, Chan SY, Gavlak J, Harman K, Ismail-Koch H, Kingshott RN, Langley R, Morley A, *et al*: British thoracic society guideline for diagnosing and monitoring paediatric sleep-disordered breathing. *Thorax* 78: sl-s27, 2023.
58. Artero A, Madrazo M, Fernández-Garcés M, Miguez AM, García AG, Vieitez AC, Guijarro EC, Aizpuru EM, Gómez MG, Manrique MA, *et al*: Severity scores in COVID-19 pneumonia: A multicenter, retrospective, cohort study. *J Gen Intern Med* 36: 1338-1345, 2021.
59. Asai N, Watanabe H, Shiota A, Kato H, Sakanashi D, Hagihara M, Koizumi Y, Yamagishi Y, Suematsu H and Mikamo H: Efficacy and accuracy of qSOFA and SOFA scores as prognostic tools for community-acquired and healthcare-associated pneumonia. *Int J Infect Dis* 84: 89-96, 2019.
60. Toori KU, Qureshi MA, Chaudhry A and Safdar MF: Neutrophil to lymphocyte ratio (NLR) in COVID-19: A cheap prognostic marker in a resource constraint setting. *Pak J Med Sci* 37: 1435-1439, 2021.
61. Ulloque-Badaracco JR, Salas-Tello W, Al-kassab-Córdova A, Alarcón-Braga EA, Benites-Zapata VA, Maguiña JL and Hernandez AV: Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 patients: A systematic review and meta-analysis. *Int J Clin Pract* 75: e14596, 2021.
62. Pasiñ L, Navalesi P, Zangrillo A, Kuzovlev A, Likhvantsev V, Hajjar LA, Fresilli S, Lacerda MVG and Landoni G: Corticosteroids for patients with coronavirus disease 2019 (COVID-19) with different disease severity: A meta-analysis of randomized clinical trials. *J Cardiothorac Vasc Anesth* 35: 578-584, 2021.
63. Preetam M and Anurag A: MuLBSTA score in COVID-19 pneumonia and prediction of 14.day mortality risk: A study in an Indian cohort. *J Family Med Prim Care* 10: 223-227, 2021.
64. Micó-Gandia J, Pina-Belmonte A, Aguilera-Ayllón A, Carmona-Martín M, Piles-Roger L, Martínez-Reig M, Artero-Mora M: CO-121-MULBSTA, PSI y CURB65, predicción de pronóstico en pacientes con COVID-19. *Rev Clin Esp* 1: 221, 2021 (In Spanish).
65. Schumacher AE, Kyu HH, Aali A, Abbafati C, Abbas J, Abbasgholizadeh R, Abbasi MA, Abbasian M, Abd ElHafeez S, Abdelmasseh M, *et al*: Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: A comprehensive demographic analysis for the global burden of disease study 2021. *Lancet* 8: S0140-S6736, 2024.
66. Ruggeri P and Esquinas A: Fibrosis-4 (FIB-4) index and mortality in COVID-19 patients admitted to the emergency department: a new interesting predictive index for patients with COVID-19 disease? *Intern Emerg Med* 17: 2451-2452, 2022.
67. Estella A: Usefulness of CURB-65 and pneumonia severity index for influenza A H1N1v pneumonia. *Monaldi Arch Chest Dis* 77: 118-121, 2015.
68. Armiñanzas C, de Las Revillas FA, Cuadra MG, Arnaiz A, Sampedro MF, González-Rico C, Ferrer D, Mora V, Suberviola B, Latorre M, *et al*: Usefulness of the COVID-GRAM and CURB-65 scores for predicting severity in patients with COVID-19. *Int J Infect Dis* 108: 282-288, 2021.
69. Ahn JH and Choi EY: Expanded A-DROP score: A new scoring system for the prediction of mortality in hospitalized patients with community-acquired pneumonia. *Sci Rep* 8: 14588, 2018.
70. Power L, Mullally D, Gibney ER, Clarke M, Visser M, Volkert D, Bardon L, de van der Schueren MAE and Corish CA; MaNuEL Consortium: A review of the validity of malnutrition screening tools used in older adults in community and healthcare settings-A MaNuEL study. *Clin Nutr ESPEN* 24: 1-13, 2018.
71. Ranganathan P and Aggarwal R: Common pitfalls in statistical analysis: Understanding the properties of diagnostic tests-Part 1. *Perspect Clin Res* 9: 40-43, 2018.

